29
Participants
Start Date
March 31, 2009
Primary Completion Date
August 31, 2010
Study Completion Date
May 31, 2011
IPI-504
IPI-504 IV infusion 300 mg/m2
Trastuzumab
Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
Memorial Sloan-Kettering Cancer Center, New York
Weill Cornell Breast Center, New York
Peachtree Hematology-Oncology Consultants, P.C., Atlanta
Medical College of Georgia Cancer Center, Augusta
Florida Cancer Research Institute, Davie
Boca Raton Comphrensive Cancer Care, Boca Raton
West Cancer Clinic, Memphis
US Oncology, Dallas
Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs
Dana-Farber Cancer Institute, Boston
Vall d'Hebron Institute of Oncology (V.H.I.O.), Barcelona
Lead Sponsor
Infinity Pharmaceuticals, Inc.
INDUSTRY